Statement: the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 18/52 (34.62%)   Anaemia 2/52 (3.85%)   Febrile Neutropenia 1/52 (1.92%)   Haemolytic Uraemic Syndrome 1/52 (1.92%)   Leukopenia 1/52 (1.92%)   Neutropenia 1/52 (1.92%)   Thrombocytopenia 1/52 (1.92%)   Cardiac Failure Congestive 1/52 (1.92%)   Cardio-Respiratory Arrest 1/52 (1.92%)   Abdominal Pain 1/52 (1.92%)   Constipation 1/52 (1.92%)   Diarrhoea 1/52 (1.92%)
Secondary_evidence: Adverse Events 1:   Total: 14/54 (25.93%)   anaemia 2/54 (3.70%)   Febrile neutropenia 7/54 (12.96%)   Neutropenia 2/54 (3.70%)   Thrombocytopenia 6/54 (11.11%)   Atrial fibrillation 1/54 (1.85%)   Cardiac failure congestive 1/54 (1.85%)   Pericardial effusion 1/54 (1.85%)   Nausea 2/54 (3.70%)   Vomiting 3/54 (5.56%)   Catheter site erythema 1/54 (1.85%)   Chest discomfort 1/54 (1.85%) Adverse Events 2:   Total: 5/20 (25.00%)   anaemia 0/20 (0.00%)   Febrile neutropenia 2/20 (10.00%)   Neutropenia 0/20 (0.00%)   Thrombocytopenia 0/20 (0.00%)   Atrial fibrillation 0/20 (0.00%)   Cardiac failure congestive 0/20 (0.00%)   Pericardial effusion 0/20 (0.00%)   Nausea 0/20 (0.00%)   Vomiting 0/20 (0.00%)   Catheter site erythema 0/20 (0.00%)   Chest discomfort 0/20 (0.00%)